Skip to main content
22 search results for:

Anti-CD20 antibodies 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 19-12-2022 | Systemic lupus erythematosus | News | Article

    Anti-dsDNA antibodies have potential to guide targeted therapy use in SLE

    An exploratory analysis of data from the phase 2b BEAT LUPUS trial suggests that IgA2 anti-dsDNA antibody levels may be able to predict response to B cell-targeted therapies in patients with systemic lupus erythematosus.

  2. 20-05-2022 | TNF inhibitors | Adis Journal Club | Article
    Rheumatology and Therapy

    Association between TNFi anti-drug antibodies, smoking, and disease activity in patients with inflammatory arthritis: Results from a Norwegian cross-sectional observational study

    DOI [Teaser] Key Summary Points Real-life studies on the clinical impact of neutralizing TNFi anti-drug antibodies (nADAb) including a broad range of disease activity metrics are needed, as well as studies exploring the impact of smoking on formation of nADAb.

  3. 14-02-2022 | COVID-19 | News | Article
    News in brief

    Most RMD patients retain antibodies 6 months after COVID-19 vaccination

    Among people with rheumatic and musculoskeletal diseases, levels of antibodies against SARS-CoV-2 decrease in the 6-month period following two doses of mRNA vaccines, but remain above the threshold of predicted neutralizing ability in the majority of patients, research suggests.

  4. 03-11-2021 | COVID-19 | News | Article
    News in brief

    COVID-19 vaccines have ‘acceptable safety profile’ in people with antiphospholipid antibodies

    Study findings suggest that mRNA COVID-19 vaccines have a favorable short-term safety profile in people with antiphospholipid antibodies.

  5. 07-09-2020 | Rheumatoid arthritis | News | Article

    Anti-CarbV antibodies show treatment biomarker potential in RA

    Anti-carbamylated vimentin antibodies may be associated with treatment response and structural damage progression among patients with rheumatoid arthritis, shows a post-hoc analysis of data from the phase 3 RA-BEGIN trial.

  6. 15-01-2020 | Myositis | Highlight | Teaser
    Expert Opinion: Editorial

    Do myositis-specific antibodies have an impact on the treatment of idiopathic inflammatory myopathies?

    Latika Gupta and Rohit Aggarwal evaluate the use of myositis-specific antibodies in the classification and management of this disease.

  7. 15-01-2020 | Myositis | Editorial | Article

    Do myositis-specific antibodies have an impact on the treatment of idiopathic inflammatory myopathies?

    Latika Gupta and Rohit Aggarwal evaluate the use of myositis-specific antibodies in the classification and management of this disease.

  8. 10-03-2018 | ANCA-associated vasculitis | Review | Article

    Anti-neutrophil cytoplasmic antibodies and their clinical significance

    Anti-neutrophil cytoplasmic antibodies (ANCA) are a group of autoantibodies that cause systemic vascular inflammation by binding to target antigens

  9. 05-02-2018 | TNF inhibitors | News | Article

    Antidrug antibodies may contribute to TNF inhibitor failure in arthritis patients

    The development of antidrug antibodies against adalimumab or infliximab, but not etanercept, may play a role in the development of secondary treatment failure among patients with rheumatoid arthritis or spondyloarthritis, researchers report.

  10. 30-03-2017 | Rheumatoid arthritis | News | Article

    Anticollagen antibodies predict favorable prognosis in RA

    Antifibrillar collagen type II antibodies are associated with a favorable inflammatory outcome among patients with rheumatoid arthritis, researchers report.

  11. 14-06-2018 | Systemic lupus erythematosus | Article

    Anti-carbamylated protein antibodies as a new biomarker of erosive joint damage in systemic lupus erythematosus

    Ceccarelli F et al. Arthritis Res Ther 2018; 20: 126. doi: 10.1186/s13075-018-1622-z

  12. 19-11-2015 | Systemic lupus erythematosus | Review | Article

    Anti-DNA antibodies — quintessential biomarkers of SLE

    Antibodies that recognize and bind to DNA are in regular use as biomarkers for diagnosis of systemic lupus erythematosus. This review highlights current and future challenges of such biomarkers.  Nat Rev Rheumatol 2016;12:102–110. doi:10.1038/nrrheum.2015.151

  13. 11-05-2022 | COVID-19 | News | Article

    Type, intensity of immunomodulatory therapy ‘of major relevance’ for COVID-19 vaccine response

    Seroconversion was defined as anti-receptor binding domain (RBD) immunoglobulin G antibodies of more than 4 AU/mL.

  14. 12-10-2021 | Lupus nephritis | News | Article

    Add-on obinutuzumab shows promise for proliferative lupus nephritis

    Findings from the phase 2 NOBILITY trial suggest that the addition of the type II anti-CD20 antibody obinutuzumab to standard therapy may improve renal outcomes for patients with proliferative lupus nephritis.

  15. 10-11-2021 | ACR 2021 | Conference coverage | Article

    Increased risk for breakthrough COVID-19 infection in vaccinated patients with AIRDs

    And among those who were subsequently hospitalized, 10 (46%) were taking CD20 inhibitors and seven (32%) were on anti-metabolites, specifically mycophenolate.

  16. 13-09-2021 | COVID-19 | News | Article

    Study identifies predictors of COVID-19 vaccine response in rituximab-treated patients

    Among people treated with anti-CD20 B cell-depleting agents, timing of treatment and numbers of circulating CD4+ and CD19+ cells are significant predictors of immune responses to messenger (m)RNA vaccines against SARS-CoV-2, shows the RituxiVac study.

  17. 07-09-2021 | COVID-19 | News | Article

    COVID-19 vaccination: Meta-analysis confirms reduced seroconversion rates in people with IMIDs

    However, they report that seroconversion rates were “much lower” in people taking anti-CD20 antibodies such as rituximab (39.0%) or the anti-CTLA-4 therapy abatacept.

  18. 05-06-2021 | EULAR 2021 | Conference coverage | Article

    Pfizer–BioNTech vaccine immunogenicity confirmed in patients with AIIRDs

    Furer noted that the significantly reduced seropositivity rate of 39% among the 12.7% of patients taking the anti-CD20 antibody rituximab as monotherapy was affected by the prevaccination timing of drug administration.

  19. 07-06-2019 | Rheumatoid arthritis | Case study | Article

    Tofacitinib in a patient with refractory severe rheumatoid arthritis

    Tumor necrosis factor inhibitors (etanercept, adalimumab, infliximab, golimumab, and certolizumab pegol), anti-CD20 monoclonal antibodies (rituximab), T-cell costimulation inhibitors (abatacept) and anti-interleukin-6 receptor antibodies (tocilizumab and sarilumab) have all shown efficacy in the management of RA .

  20. 29-01-2019 | Lupus nephritis | Editorial | Article

    Emerging therapies for lupus nephritis

    Table 1: Recent and ongoing trials of emerging therapeutics in lupus nephritis B-cell targeted therapies Anti-CD20 Three monoclonal antibodies (mAbs) targeting CD20 have been evaluated in LN: rituximab (RTX); obinutuzumab; and ocrelizumab.

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.